Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Interim results from the ZUMA-1 trial of novel CAR-T cells against non-Hodgkin lymphoma

ASH 2016

Published: 6 Dec 2016

Views: 2944

Rating:

Save

Dr Sattva Neelapu - MD Anderson Cancer Center, Houston, USA

Dr Neelapu speaks with ecancertv at ASH 2016 about interim results from a phase II multicenter trial of KTE-C19 (anti-CD19 CAR T Cells) in patients with chemorefractory primary mediastinal B-Cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL)

ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Related Videos

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

Multiple myeloma treatment in Dakar: Epidemiological, diagnostic, and...

Dr Nata Dieng - Hôpital Principal de Dakar, Dakar, Senegal

Multiple myeloma treatment in Dakar: Epidemiological, diagnostic, and therapeutic aspects ( Dr Nata Dieng - Hôpital Principal de Dakar, Dakar, Senegal )

Relapsed Refractory Multiple Myeloma

Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India

$Relapsed Refractory Multiple Myeloma ( Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India )$

The evolving paradigm in management of Multiple Myeloma

D Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India

The evolving paradigm in management of Multiple Myeloma ( D Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India )

Dr Nita Nair - Apollo Cancer Centres, Mumbai

Breast Cancer ( Dr Nita Nair - Apollo Cancer Centres, Mumbai )

Epitope editing enables targeted immunotherapy of acute myeloid leukaemia

Dr Gabriele Casirati - Dana-Farber Cancer Institute, Boston, USA

Epitope editing enables targeted immunotherapy of acute myeloid leukaemia ( Dr Gabriele Casirati - Dana-Farber Cancer Institute, Boston, USA )

Molecular oncology and translational medicine

Dr Gregg Fields - Florida Atlantic University, Florida, USA

Molecular oncology and translational medicine ( Dr Gregg Fields - Florida Atlantic University, Florida, USA )

COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity...

Dr Sumanta K. Pal - City of Hope Comprehensive Cancer Center, Duarte, USA

COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity in inoperable locally advanced/metastatic urothelial carcinoma ( Dr Sumanta K. Pal - City of Hope Comprehensive Cancer Center, Duarte, USA )

More from ecancer